Keyphrases
Body Composition
100%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
100%
Cancer Center
100%
Hazard Ratio
81%
Overall Survival
45%
Subcutaneous Adipose Tissue
45%
Progression-free Survival
45%
Non-small Cell Lung Cancer (NSCLC)
36%
Female Patients
27%
Chemotherapy
27%
Adipose Tissue Mass
27%
Computed Tomography
18%
Monotherapy
18%
Male Patients
18%
Skeletal muscle Mass
18%
Body Composition Assessment
18%
Kaplan-Meier Analysis
18%
Oncological Outcomes
18%
Patient Cohort
9%
Poor Outcome
9%
Clinical Data
9%
Cohort Analysis
9%
Slice Selection
9%
Visceral Adipose Tissue
9%
Systemic Therapy
9%
Skeletal muscle
9%
Hounsfield Units
9%
Chemoimmunotherapy
9%
Density Change
9%
Cancer Outcomes
9%
Phase 1/2 Study
9%
Skeletal muscle Area
9%
Tissue Compartments
9%
Body Compartments
9%
Multi-cohort Studies
9%
Deep Neural Network
9%
Durvalumab
9%
Lung Cancer Prognosis
9%
Single Institution Study
9%
In(III)
9%
Computed Tomography Attenuation
9%
INIS
cancer
100%
body composition
100%
immunotherapy
100%
lung cells
100%
patients
50%
hazards
50%
adipose tissue
33%
muscles
22%
data
16%
females
16%
computed tomography
16%
density
16%
chemotherapy
16%
males
11%
losses
11%
compartments
11%
women
5%
therapy
5%
comparative evaluations
5%
units
5%
design
5%
metastases
5%
attenuation
5%
neural networks
5%
Medicine and Dentistry
Malignant Neoplasm
100%
Non Small Cell Lung Cancer
100%
Immunotherapy
100%
Hazard Ratio
75%
Adipose Tissue
50%
Overall Survival
41%
Progression Free Survival
41%
Skeletal Muscle
33%
Computer Assisted Tomography
25%
Monotherapy
16%
Kaplan Meier Method
16%
Systemic Therapy
8%
Arm
8%
Cancer Prognosis
8%
Chemoimmunotherapy
8%
Durvalumab
8%
Immunology and Microbiology
Body Composition
100%
Adipose Tissue
100%
Immunotherapy
100%
Overall Survival
83%
Progression Free Survival
83%
Skeletal Muscle
66%
Computer Assisted Tomography
50%
Arm
16%
Durvalumab
16%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Non Small Cell Lung Cancer
100%
Immunotherapy
100%
Overall Survival
41%
Progression Free Survival
41%
Chemotherapy
25%
Monotherapy
16%
Cancer Prognosis
8%
Durvalumab
8%
Biochemistry, Genetics and Molecular Biology
Body Composition
100%
Overall Survival
83%
Progression Free Survival
83%
Skeletal Muscle
66%
Computer Assisted Tomography
50%
Neuroscience
Adipose Tissue
100%
Immunotherapy
100%
Skeletal Muscle
66%
Computed Tomography
50%
Neural Network
16%
Chemoimmunotherapy
16%
Durvalumab
16%